Amgen (AMGN) Cash & Equivalents (2009 - 2026)

Amgen has reported Cash & Equivalents for 18 years, with the latest figure at $14.0 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 74.25% year-over-year to $14.0 billion in Q2 2026; TTM through Jun 2026 was $14.0 billion, a 74.25% increase from a year earlier, with the FY2025 full-year figure at $9.1 billion, down 23.75% from the prior year.
• Cash & Equivalents was $14.0 billion for Q2 2026 at Amgen, up from $12.0 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $34.7 billion in Q3 2023, with the low at $5.2 billion in Q2 2022.
• Average Cash & Equivalents over 5 years is $13.4 billion, with a median of $9.5 billion recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 558.24% in 2023, then slumped 74.06% in 2024.
• Over 5 years, Cash & Equivalents stood at $7.6 billion in 2022, then jumped by 43.45% to $10.9 billion in 2023, then grew by 9.4% to $12.0 billion in 2024, then declined by 23.75% to $9.1 billion in 2025, then soared by 53.24% to $14.0 billion in 2026.
• The last three Cash & Equivalents figures came in at $14.0 billion (Q2 2026), $12.0 billion (Q1 2026), and $9.1 billion (Q4 2025), per Business Quant data.